JAKAVI is now approved for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. Get important safety information at http://www.jakavi.com/Safety.jsp
DISCLAIMER: DMOZing.com is not affiliated in any way, shape, or form with DMOZ, AOL, Netscape, their management, entities or their official websites. Links to external websites on this website does not constitute endorsement.